Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | IDH2 | P48735 | 4/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165886 | 0.93 | SCN9A (0.46) | SCN9AIDH2ALOX5APFEN1TSHR | |
| SCHEMBL5178711 | 0.93 | SCN9A (0.46) | SCN9AIDH2ALOX5APFEN1TSHR | |
| SCHEMBL5165878 | 0.93 | SCN9A (0.46) | SCN9AIDH2ALOX5APFEN1TSHR | |
| SCHEMBL5066850 | 0.93 | SCN9A (0.48) | SCN9AIDH2ALOX5APFEN1CHEK2 | |
| SCHEMBL13397358 | 0.84 | SCN9A (0.47) | SCN9AALOX5APFEN1CHEK2GLS | |
| SCHEMBL2031191 | 0.84 | SCN9A (0.47) | SCN9AALOX5APFEN1CHEK2GLS | |
| SCHEMBL5164315 | 0.81 | IDH2 (0.46) | IDH2TSHRCYP2C9CHEK1 | |
| SCHEMBL5063309 | 0.80 | HCRTR1 (0.48) | IDH2CHEK1 | |
| SCHEMBL13997114 | 0.80 | IDH2 (0.47) | SCN9AIDH2TSHRCHEK1 | |
| Hydrochloric Acid SCHEMBL5063346 | 0.79 | IDH2 (0.47) | SCN9AIDH2TSHRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318974-A1 | Compounds Useful for Inhibiting Chk1 | ICOS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318974-A1 | Compounds Useful for Inhibiting Chk1 | CHEK1, PCNA, CHEK2 | SCN9A 4533/4885IDH2 742/4885ALOX5AP 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.